Bioequivalence of ketoconazole capsules in Chinese healthy volunteers

Cheng-ke Huang,Xiang-jun Qiu,Peng Xu,Guo-xin Hu,Zong-shun Dai
DOI: https://doi.org/10.3969/j.issn.1001-8689.2006.07.018
2006-01-01
Abstract:Objective: To study the relative bioavailability and bioequivalence of ketoconazole capsules in healthy volunteers. Methods: A single oral dose (400mg of tested and reference formulation) were given to 20 healthy volunteers in a randomized crossover study. The concentrations of ketoconazole in plasma were determined by HPLC. The pharmacokinetic parameters were calculated and the bioavailability and bioequivalence of two formulations were evaluated by DAS program. Results: After a single dose, the pharmacokinetic parameters for ketoconazole tested and reference groups were as follows: cmax were (13.69 ± 1.03) mg/L and (13.20 ± 1.34) mg/L; tmax were (1.50 ± 0.23)h and (1.50 ± 0.23)h; AUC(0-24) were (101.39 ± 16.26) mg · h/L and (94.52 ± 17.43)mg · h/L; AUC(0-inf) were (105.73 ± 17.85)mg · h/L and (97.67 ± 18.01)mg ·h/L, respectively. The 90% confidential interval of cmax, AUC(0-120) and AUC(0-inf) of tested formulation were 100.93% ∼ 107.00%, 101.19% ∼ 114.27% and 101.45% ∼ 115.78%, respectively. Conclusions: The relative bioavailability was (108.7 ± 16.0)%. The results of the statistic analysis showed that the two formulations were bioequivalence.
What problem does this paper attempt to address?